A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor
© Weber et al; licensee BioMed Central Ltd. 2007
Received: 29 September 2006
Accepted: 12 February 2007
Published: 12 February 2007
Bone morphogenetic proteins (BMPs) are key regulators in the embryonic development and postnatal tissue homeostasis in all animals. Loss of function or dysregulation of BMPs results in severe diseases or even lethality. Like transforming growth factors β (TGF-βs), activins, growth and differentiation factors (GDFs) and other members of the TGF-β superfamily, BMPs signal by assembling two types of serine/threonine-kinase receptor chains to form a hetero-oligomeric ligand-receptor complex. BMP ligand receptor interaction is highly promiscuous, i.e. BMPs bind more than one receptor of each subtype, and a receptor bind various ligands. The activin type II receptors are of particular interest, since they bind a large number of diverse ligands. In addition they act as high-affinity receptors for activins but are also low-affinity receptors for BMPs. ActR-II and ActR-IIB therefore represent an interesting example how affinity and specificity might be generated in a promiscuous background.
Here we present the high-resolution structures of the ternary complexes of wildtype and a variant BMP-2 bound to its high-affinity type I receptor BMPR-IA and its low-affinity type II receptor ActR-IIB and compare them with the known structures of binary and ternary ligand-receptor complexes of BMP-2. In contrast to activin or TGF-β3 no changes in the dimer architecture of the BMP-2 ligand occur upon complex formation. Functional analysis of the ActR-IIB binding epitope shows that hydrophobic interactions dominate in low-affinity binding of BMPs; polar interactions contribute only little to binding affinity. However, a conserved H-bond in the center of the type II ligand-receptor interface, which does not contribute to binding in the BMP-2 – ActR-IIB interaction can be mutationally activated resulting in a BMP-2 variant with high-affinity for ActR-IIB. Further mutagenesis studies were performed to elucidate the binding mechanism allowing us to construct BMP-2 variants with defined type II receptor binding properties.
Binding specificity of BMP-2 for its three type II receptors BMPR-II, Act-RII and ActR-IIB is encoded on single amino acid level. Exchange of only one or two residues results in BMP-2 variants with a dramatically altered type II receptor specificity profile, possibly allowing construction of BMP-2 variants that address a single type II receptor. The structure-/function studies presented here revealed a new mechanism, in which the energy contribution of a conserved H-bond is modulated by surrounding intramolecular interactions to achieve a switch between low- and high-affinity binding.
Bone morphogenetic proteins (BMPs) and other members of the transforming growth factor-β (TGF-β) superfamily, like the activins, growth and differentiation factors (GDFs) and TGF-βs are secreted signaling proteins that regulate the development, maintenance and regeneration of tissues and organs [1–4]. Their importance in the development of multicellular organisms is visible from their existence in all vertebrates and non-vertebrate animals. The number of different TGF-β members correlates with the complexity of the organism, with four members found in C. elegans , seven members in D. melanogaster  and more than 30 members in men . Dysregulation of signaling of TGF-β like proteins leads to a variety of diseases, including skeletal malformations , osteoporosis , cardiovascular and metabolic diseases , muscular disorders , and cancer .
Members of the TGF-β superfamily bind two different types of serine/threonine-kinase receptors termed type I and type II receptors [2, 13, 14]. Both receptor subtypes share a common architecture, i.e. a small extracellular ligand binding domain, a single transmembrane segment and a cytoplasmic serine/threonine-kinase domain. The kinase domains of type I and type II receptors share a high level of amino acid sequence similarity. However a glycine/serine-rich segment – the GS box – in the membrane-proximal part of the intracellular domain is unique to the type I receptors. In general, ligand binding induces hetero-oligomerization of type I and type II receptors initiating the intracellular signaling cascade. The constitutively active type II serine/threonine-kinase transphosphorylates the type I receptor at the GS box thereby activating the type I kinase . The latter subsequently activates SMAD proteins, which dimerize and migrate to the nucleus, where they, in concert with other proteins, function as transcription factors to regulate responsive genes [16, 17]. Two SMAD pathways exist. SMAD-2/-3 are activated by activins and TGF-βs and SMAD-1/-5/-8 are activated by BMPs and a subset of GDFs. Recent discoveries however show that other signaling pathways involving the MAP kinase pathway or small G proteins like Ras might be directly addressed by TGF-β members . Proteomics approaches also identified various adaptor and other proteins associated with the intracellular domain of the BMP type II receptor suggesting that signaling of TGF-βs and BMPs might be more complex than the well-examined SMAD pathway .
Signal transduction of TGF-β proteins is highly controlled at several levels; a manifold of modulator proteins in the extracellular space vary the activities of these factors . Although they are often termed antagonists there are also examples of modulator proteins leading to an increase in receptor-mediated activity . Pseudo receptors as well as co-receptors can either inhibit or modulate signaling at the membrane surface level [22, 23]. Inside the cell various possibilities exist to adjust or interrupt the activity, e.g. by inhibitory SMAD proteins, phosphatases to counteract the receptor kinase activity , ubiquitination-dependent proteolysis of the receptors/SMADs [25, 26] or by transcriptional repressors .
One important feature of the TGF-β superfamily is the limited specificity of its ligand-receptor interactions. For more than 30 ligands only seven type I receptors and five type II receptors are known. Thus one receptor of a particular subtype has to bind several different ligands. But even though the ligands outnumber the available receptors, several BMPs and GDFs have been shown to interact with several different receptor chains of both type I and type II. However, preferences seem to exist. For instance BMP-2 uses preferentially BMPR-IA and BMPR-IB less so , GDF-5 prefers BMPR-IB  and BMP-7 ActR-I . An especially intriguing situation exists with the type II activin receptors ActR-II and ActR-IIB which interact with different BMPs, activins, GDF-8/-11 and Nodal [15, 31]. Ligand specific patterns seem to exist for type I and type II receptors. Recent clinical and biochemical studies on GDF-5 have shown that the receptor specificity profile of a ligand can be absolutely crucial for its biological functions [32, 33]. This underlines the importance of understanding the molecular mechanisms by which these relative binding affinities are generated.
In the present study we analyze the interaction of BMP-2 with its type I receptor BMPR-IA and its type II receptor ActR-IIB. BMP-2 is a prototypical member of the TGF-β superfamily with respect to ligand-receptor promiscuity. It binds with high-affinity to both type I receptors BMPR-IA and BMPR-IB; three different type II receptors, i.e. BMPR-II, ActR-II and ActR-IIB can be recruited to yield a signaling hetero-oligomeric complex [15, 34]. The usage of the activin type II receptors is especially interesting as they exhibit a dual specificity and affinity [29, 30, 35, 36]. ActR-II and ActR-IIB bind activin A (Act-A) with high affinity in the low nanomolar range leading to activation of the SMAD-2/-3 pathway, whereas binding of BMP-2 occurs with low-affinity in the micromolar range resulting in the activation of the SMAD-1/-5/-8 pathway. Since Act-A and BMPs can exhibit opposing activities [37, 38], which are regulated by competition for the activin type II receptors, it is important to know how the binding affinity to both ligand subgroups activins and BMPs can be changed by orders of magnitude.
Here we describe in a structure-/function analysis how binding specificity of the type II receptor ActR-IIB for different ligands as well as of BMP-2 for different type II receptors is encoded on a single-amino acid level. A single mutation in BMP-2 selectively enhances the binding affinity for BMPR-II. Exchange of two other amino acids results in a nearly 100-fold increase in affinity particular for type II receptor ActR-IIB without affecting the binding affinities to the other receptors. Remarkably, a "silent H-bond" is thereby converted into a hot spot of binding energy, which also exists in Act-A.
Architecture and assembly of the ternary ligand-receptor complex
Inspection of the receptor-ligand interactions of both BMP-2/receptor complexes (comprising BMP-2 L100K/N102D, in the following termed ternary complex (1:2:2), or wildtype BMP-2, in the following termed ternary complex (1:1:1)) demonstrates that the ligand-receptor interfaces are highly similar. Superposition of the complexes yields an r.m.s. deviation of 0.3 Å for the Cα atoms of BMP-2 (in the ternary complex (1:1:1) only "bound" parts of BMP-2 were considered), and 0.4 Å for the Cα of BMP-2 and ActR-IIBECD (see Additional file 2). Thus, the different crystal forms and the employed mutant protein did not alter the general fold or the assembly of BMP-2 and the receptors. This indicates that the core parts of these proteins are rigid and that no major conformational changes take place during complex formation.
The type I receptor BMPR-IAECD occupies the wrist epitope of BMP-2 (Figs. 1 and 2a,b), whereas the type II receptor ActR-IIBECD is located on top of finger 1 of BMP-2 consistent with the knuckle epitope identified by mutagenesis [28, 39]. This binding site overlaps almost perfectly with that of ActR-IIB in the structures of the Act-A:(ActR-IIBECD)2 complex [41, 42]. A comparison with the ActR-II binding site in the structure of the complex BMP-7:(ActR-IIECD)2  shows that the site of ActR-II however is shifted slightly away from the fingertips. In the recently published structure of another BMP-2 ternary ligand-receptor complex comprising of BMPR-IAECD and ActR-IIECD , the binding site of ActR-II is, however, identical with that of ActR-IIB in our complex structures. This observation suggests that the type II receptor location in the knuckle epitope is probably dependent on the nature of the ligand, here BMP-2 or BMP-7. The slight shift of the epitope might represent one possible mechanism for generating ligand specific receptor recognition.
In contrast, in other TGF-β ligand-receptor complexes, e.g. Act-A:ActR-IIBECD and TGF-β3:TβR-II, the ligand structures differ vastly in the free and bound form [41, 42, 44, 45]. The cause for the large changes in the dimer architecture of Act-A and TGF-βs is yet unclear, but is probably not due to receptor binding itself. Inspection of the backbone dynamics in TGF-β3 using NMR-relaxation methods reveals an inherent flexibility in the TGF-β molecule , which might result in an dynamic equilibrium between an open and a closed dimer architecture for TGF-βs and possibly also activins . In contrast, BMP-2 seems not to change its overall dimer architecture upon binding to either type I or both receptor subtypes. Accordingly, in the absence of gross conformational changes binding affinities of ActR-IIB for BMP-2 alone or for BMP-2 complexed with BMPR-IAECD are identical (see Additional file 3). Our current structural data also excludes the possibility that the binding cooperativity for the type II receptor observed for BMP-2 in cell-based experiments  results from direct contacts between the receptor ectodomains as proposed for the TGF-βs [44, 47]. The closest proximity between the ectodomains of either subtype measures about 12 Å (Fig. 2c,d). Involvement of the intracellular domains of the receptors in the generation of binding cooperativity has been ruled out by binding experiments using truncated receptors .
An alternative model suggests interaction of the transmembrane segments as a possible source for cooperativity. However, the distance between the C-termini of both ActR-IIBECD (Fig. 2c) is about 85 Å and the C-termini of BMPR-IAECD are separated by approx. 70 Å. The distance between the traceable C-termini of the receptor ectodomains BMPR-IA and ActR-IIB measures about 40 Å. Modeling of the missing C-terminal peptide sequences – no electron density is observed for the six C-terminal residues of BMPR-IAECD and 20 residues of ActR-IIBECD – shows that contacts between all four transmembrane helices are impossible due to steric restraints by the ligand. Only hetero-dimeric interactions between the transmembrane helices of one BMPR-IA and one ActR-IIB receptor residing on the same half of the BMP-2 ligand are possible (see also discussion in Allendorph et al. ).
Ternary complex formation does not alter type I ligand-receptor core interface
Although the global fold of BMP-2 is not affected by the binding of both receptor subtypes, small locally restricted changes in backbone and side chain conformations are observed in the wrist and knuckle epitopes of both ternary complexes. The binding of BMP-2 to its high-affinity receptor BMPR-IAECD causes a local induced fit in the so-called pre-helix segment (Pro48-Asn56) of BMP-2 . In free BMP-2 this segment exhibits high temperature factors but upon type I receptor binding temperature factors within this segment drop to low values also observed in the core of the binary complex BMP-2:BMPR-IAECD.
For the recently published structure of the ternary ligand-receptor complex of BMP-2 bound to BMPR-IA and ActR-II, no such rearrangement for the type I receptor binding has been described . A detailed comparison of this complex structure with those of this study reveals that the change in type I receptor orientation is significantly smaller; the tilt angle of BMPR-IA changes by only 3° compared to its location in the BMP-2:BMPR-IAECD binary complex. Consistently, the change in backbone conformation of the β-strands 6 and 7 of BMP-2 in the complex of Allendorph et al. is also smaller, e.g. the distance between the Cα atoms of Asn102 of the binary and ternary complex is 1 Å (for comparison the distance between the Cα atoms of Asn102 of the binary complex and the ternary complexes of this study is roughly 2 Å, see Fig. 3b). Although the physiological role of the type I receptor rearrangement is yet unknown – our BIAcore study clearly shows that type II receptor ectodomain binding to BMP-2 is independent of the presence of a type I receptor – the comparison suggests that the different change in type I receptor orientation might be dependent on the nature of the type II receptor.
Analysis of solvent molecules in the BMP-2 type I receptor interface has shown that the main-binding determinants of the BMP-2 – type I receptor interaction are surrounded by tightly bound water molecules, which seem to play an important role in the ligand-receptor recognition mechanism. Of these water molecules in the type I receptor-ligand interface of the binary complex , all (four in the core, three additional in the periphery) are found in identical positions in the ternary complexes of this study and the ternary complex structure published by Allendorph et al.  although the crystallization conditions differ significantly. This corroborates our hypothesis that interface water molecules play an important role in the ligand-type I receptor recognition possibly by generating a major part of the structural plasticity of BMP-2 . In summary, despite the reorientation of BMPR-IA upon recruitment of the type II receptor ectodomain, the binding epitope of the type I receptor remains unaltered.
The ligand-type II receptor core interface is predominantly hydrophobic
The type II receptor binding site of BMP-2 exhibits a convex shape with no deep pockets and is predominantly hydrophobic (Fig. 4b). The hydrophobic amino acids are in the center and surrounded by a ring of polar and charged residues. The core interface residue of ActR-IIB, i.e. Trp60, Tyr42 Leu61, Lys56, V55, and Val81, exhibit large accessible surface areas in the unbound state, which become buried by 60 to 100% upon complex formation (Fig. 4b,c). The knuckle epitope of BMP-2 has a complementary hydrophobic surface with a horseshoe-like form (Fig. 4b). The shape results from the central Ser88, which is embedded, in the hydrophobic patch together with the peripheral polar side chain of Asn102.
In the complex Trp60 of ActR-IIB extends into a shallow pocket formed by Ala34, Pro35, Ser88, Leu90 and Leu100 of BMP-2 (Fig. 4b,c), all of which were identified as important determinants for type II receptor binding before . The hydrophobic area around Trp60 measures 12 by 12 Å and is devoid of any water molecules. To test the hypothesis that the majority of the binding free energy originates from hydrophobic interactions, we have used isothermal titration calorimetry. The enthalpy ΔH, which is a measure for polar interactions, is rather small for the BMP-2:ActR-IIBECD interaction (14 kcal mol-1 at 25°C), suggesting that polar interactions play a minor role for the binding affinity of BMP-2 to type II receptors. In comparison, the enthalpy for the interaction of BMP-2 and BMPR-IAECD is more than twice as large (-36 kcal mol-1). Another indication is in the temperature dependency of the enthalpy, the heat capacity change ΔCp which should have a negative value for interactions driven by the burial of hydrophobic interfaces . As a matter of fact a rather large negative value of -496 cal mol-1 K-1 was determined for the ΔCp (see Additional file 5) of the BMP-2:ActR-IIBECD interaction being consistent with the hypothesis that hydrophobic forces drive the binding of the type II receptors to BMP-2.
A comparison of the receptors ActR-IIB and ActR-II shows that the same amino acid types form the hydrophobic core around Trp60 (Fig. 5b) with 56% of the hydrophobic interface residues being identical. Most significantly, the central H-bond between receptor Leu61 (amide) and ligand Ser88 (hydroxyl group) seems to be formed in all BMP/Activin receptor complexes analyzed so far [40–43], irrespective whether ActR-IIB or ActR-II is present (Fig. 5c–e). The structural data indicate that activin type II receptor binding at the knuckle epitope is astonishingly similar in the BMPs and activins. Thus, the few side chains that differ in the ligand proteins must generate the differences observed in the relative binding affinities of the various receptor-ligand pairs.
A hydrophobic hot spot dominates the promiscuous ligand-type II receptor interaction
Mutational analysis of the ActR-IIB interface (Biosensor analysis)
Ligand proteins (immobilized)
rel. KD (app. KD in nM)
From the functional data the binding mechanism of ActR-IIB to BMP-2 or BMP-7 seems comparable (Table 1). The main binding determinant for BMP-7 is also Trp60 followed by Tyr42. Several variants show a similar loss in affinity for BMP-2 and BMP-7. Small differences exist for the variants R46A and L61P. A significant difference is in the interaction of both BMPs with Lys37 of ActR-IIB. The ActR-IIB variant K37A binds with increased affinity to BMP-7, whereas the affinity of K37A for BMP-2 drops. Modeling studies suggested that Lys37 of ActR-IIB might be one of the key residues for generating ligand specificity among different BMP members . These results obtained for BMP-7 support the hypothesis that the low-affinity binding to BMPs is determined by a hydrophobic ActR-IIB binding epitope employing virtually the same hydrophobic binding determinants.
The functional epitope of ActR-IIB for high-affinity interaction with Act-A uses the same hydrophobic main binding determinant as for binding of the BMPs. As compiled in table 1, Trp60 and Tyr42 are also crucial for binding of Act-A. The minor hydrophobic and polar determinants are of comparable importance for binding to BMPs and Act-A. Tyr42 and Leu61 seem to contribute somewhat more to Act-A than to BMP binding, whereas Lys37 and Arg46 play a likewise lesser role in Act-A binding. These small differences might contribute to ligand discrimination to some extent. However, it is probably safe to conclude that an increment in binding free energy corresponding to a low-affinity interaction is the same in binding of BMPs and Act-A, and likely the determinants for this low-affinity interaction are the same for these ligands. But in addition a further hot spot of binding is present.
A clear and probably crucial distinction of the functional Act-A binding epitope is the importance of the Leu61 amide group as revealed by comparison of the L61A and L61P variants (Table 1). The removal of the amide proton by the proline substitution leads to a 100-fold higher decrease in binding affinity (2500-fold) than the loss of the Leu61 side chain in the L61A variant (24-fold). As mentioned above BMP-2 and BMP-7 binding affinity is similar for both variants. This finding strongly suggests that the central conserved hydrogen bond, which is inactive/silent in BMP-2 and BMP-7 interaction, is active in the interaction with Act-A (Fig. 5c–e). This "switchable" H-bond seems to be responsible for the high-affinity binding of Act-A.
In conclusion, the determinant for the high-affinity binding of Act-A seems to reside in the H-bond provided by the Leu61 amide proton (which is removed in the variant L61P), whereas this central H-bond interaction does not play an important role for low-affinity interactions with the ligands BMP-2 and BMP-7.
A switch in BMP-2 for low- and high-affinity binding of ActR-IIB
Type II receptor specificity of wildtype BMP-2 and variants (Biosensor analysis)
Receptor ectodomain proteins
rel. KD (app. KD in nM)
The side chains at positions 100 and 102 exert a decisive role in affinity determination. BMP-2 variants containing the substitution L100K show a six to 20-fold increase in binding affinity for ActR-IIB. The BMP-2 double variant L100K/N102D binds to ActR-IIB with an affinity (KD ~ 140 nM) almost as high as for the interaction of Act-A with ActR-IIB (KD ~ 60 nM) (Table 2). The single mutation N102D in BMP-2 is deleterious but in combination with the exchange L100 K the affinity for ActR-IIB is further increased. The exchange of these two residues of BMP-2 therefore converts the low- into a high-affinity binding epitope and the lysine side chain seems to be the key determinant for this transformation.
Double mutant cycle of BMP-2 and ActR-IIBECD (Biosensor analysis)
Receptor ectodomain proteins
app. KD in Nm
The residues Lys100 and Asp102 are located directly above the intermolecular H-bond between BMP-2 Ser88 Oγ and ActR-IIB Leu61 amide at the opening of the horseshoe-like hydrophobic core of the epitope (Figs. 4b and 6a,b). In the structures of the Act-A:ActR-IIBECD  and the ternary complex (1:2:2) of BMP-2L100K/N102D the Lys and Asp residues form a stable intramolecular salt bridge (Fig. 6a,b). Accordingly, Lys100 and Asp102 (in BMP-2L100K/N102D) exhibit low temperature factors indicating that both residues are quite immobile. In the structure of the ternary complex (1:1:1) comprising wildtype BMP-2 the temperature factors of the equivalent residues Leu100 and Asn102 are higher than for nearby residues indicating increased flexibility. The "rigid lid" centered above the conserved H-bond between BMP-2 Ser88 Oγ and ActR-IIB Leu61 amide might provide an effective shielding from solvent access thereby enhancing the strength of this particular H-bond (Fig. 6a–c). By thus modulating the energy contribution of an existing interaction (cis effect) rather than adding a new (trans effect) one achieves the switch from low- to high-affinity.
Specificity in the BMP-2 type II receptor epitope
Individual and combined mutations at BMP-2 position 85, 86, 100 and 102 influence binding of unalike type II receptors (Table 2) suggesting that these residues determine binding specificity of BMP-2 for ActR-II, ActR-IIB and BMPR-II. The exchange of Leu100 of BMP-2 to lysine specifically increases the binding affinity for ActR-IIB, whereas binding to ActR-II and BMPR-II is basically unaffected. The double variant L100K/N102D shows a large increase in affinity for ActR-IIB, in addition the affinity for ActR-II is moderately increased (threefold), but binding to BMPR-II remains unaltered. Mutating residues Ala86 and in particular Ser85 in BMP-2 results in variants that exhibit an increased binding affinity exclusively for BMPR-II whereas binding to the activin type II receptors is either unaffected or even decreased. The specific effects of these mutations indicate that the BMP-2 knuckle epitope comprises single residues specifying relative affinities and therefore specificity for the interaction with type II receptors ActR-IIB, ActR-II and BMPR-II (Fig. 5a,b).
ActR-IIB is one of three type II receptors known to interact with BMP-2 . The ectodomains of all three type II receptors bind with low affinity to this ligand (Table 2). BMPR-II has the lowest affinity although in many cells it is the prototypic type II receptor for BMP-2. The affinity of ActR-IIB, the strongest BMP-2 binder, is about 10-fold higher. In how far these differences in low-affinity type II binding are important for BMP-2 signaling is unknown. The increase in the biological activities observed for BMP-2 variants in our study suggests that such small differences might be of functional relevance.
As shown by cross-linking experiments in whole cells, low-affinity type II receptors alone do not bind or bind only weakly to solute BMP-2 [36, 54, 55]. On the other hand BMPR-IA, the high-affinity receptor of BMP-2, is efficiently cross-linked when present alone, and in its presence cross-linking of the type II receptor proceeds efficiently [54, 55]. The BMPR-IA ectodomain binds BMP-2 in our experimental setup with a dissociation constant of 10 to 20 nM. This affinity is 100 to 200-fold higher than that of the type II chains. On the basis of this large difference in the relative affinities of the type I and type II receptors a 2-step assembly mode of the ternary complex can be postulated, where solute BMP-2 binds first to the high-affinity BMPR-IA receptor and subsequently in the membrane the binary BMP-2/type I receptor complex can associate with the type II receptor .
The affinity profile of Act-A for the type II ectodomains is completely different from BMP-2. In the present experiments the apparent KD of Act-A for ActR-IIB is about 60 nM (Act-A to ActR-II KD ~ 250 nM), typical for a high-affinity interaction. In contrast BMPR-IIECD is bound by Act-A with low affinity (KD ~ 10 μM) resembling the interaction with BMP-2. The type I activin receptor ActR-IB by itself has an exceedingly low affinity for Act-A . Chemical cross-linking in the membrane is therefore only possible in the presence of the high-affinity ActR-II/B receptors . Consequently, the assembly of the ternary activin receptor complex differs in crucial aspects from that of the BMP-2 receptor. Solute Act-A binds first to its high-affinity ActR-II/B receptors before the low-affinity ActR-IB receptor is recruited into the complex in the membrane . As a consequence the type II activin receptors play different roles and are involved in different assembly modes during BMP-2 versus activin receptor activation. In this context BMPR-II is a special case. It likely cannot signal with Act-A, since it has only a low affinity for this ligand and a high-affinity type I chain is unknown. This generally low affinity of BMPR-II for BMPs and activin possibly explains why cytoplasmatically truncated BMPR-II exerts a dominant negative effect on BMP but not on activin signaling . The truncated BMPR-II can compete with the low-affinity interaction of type II receptors and BMP-2 but not with the high-affinity interaction of ActR-II/B and activin.
The ectodomains of the ActR-II and ActR-IIB share 44% sequence identity (Fig. 7b). The affinities of BMP-2 for the two isoforms are similar (see Table 2, ). It is therefore interesting to compare the interface of BMP-2 for ActR-IIB (this study) and ActR-II . The hydrophobic core around Trp60 (ActR-IIB numbering) is remarkably conserved. Only residues Tyr42 and Tyr13 are replaced by phenylalanine residues in ActR-II, however since both tyrosine residues are no involved in H-bonds the replacement should be without affect for the binding affinity. Polar bonds at the periphery of the epitopes are different supporting the conclusion already drawn from the mutational analysis of ActR-IIB that they are not important for binding affinity. Only the central H-bond connecting BMP-2 Ser88 Oγ and Leu61 amide also exists in the complex with ActR-II. Since a BMP-2 S88A variant exhibits only a small decrease in binding affinity for ActR-II  it can be assumed that this H-bond is silent or very weak as in the complex of BMP-2 with ActR-IIB. In this context it is intriguing that the BMP-2 variants L100K and L100K/N102D have in comparison to ActR-IIB only a small effect on binding affinity for ActR-II. In particular the double variant L100K/N102D conferring high-affinity binding to ActR-IIB has a six-fold lower effect on ActR-II binding, while the single variant L100K shows no increase in affinity for ActR-II at all (Table 2). The KD value for the interaction between ActR-II and BMP-2 L100K has been reported before  to be five to eight-fold lower than for wildtype BMP-2. The reason for the discrepancy to the present results is as yet unclear. BMP-2 L100K/N102D has not been structurally analyzed in complex with ActR-II so far. Possibly, the intramolecular hydrophobic lid formed by Lys-Asp pair is less efficient in complex with ActR-II. Considering the identical side chain composition at the core of the receptor epitopes it would be surprising, however, if here an intermolecular H-bond between Lys102 of the BMP-2 variant and the backbone carbonyl of ActR-II Cys59, which is not observed in the complex with ActR-IIB, would contribute to binding affinity .
Previously, BMP-2 mutants have been generated, which function as BMP antagonists either due to disruption of the knuckle epitope  or as Noggin-blocker due to inactivation of the wrist epitope . Now new BMP-2 variants could be obtained with increased biological activity resulting from improved binding to ActR-II (L100K/N102D) or BMPR-II (S85R/A86P) (Table 2). It will be interesting to study if the "superagonist" activity of these mutant proteins will be retained in vivo, e.g. in an ectopic bone formation assay or during healing of a critical size bone defect. BMP-2 L100K/N102D may also function as an ActR-IIB blocker, even though its affinity for this receptor is still not as high as that of Act-A (Table 2) or of GDF-8/-11 (W. Sebald, unpublished). However, it is unclear whether BMP-2 variants can interact with the type I receptor ActR-IB to some extent when strongly bound to ActR-IIB. The results of the present structure/function analysis of ActR-IIB might give some clues how relative affinity/specificity to certain ligands can be mutationally altered and manipulated. This might become useful for the design of receptor ectodomain constructs, which can specifically inhibit certain BMPs, GDFs, activins, or other ligands of the TGF-β superfamily.
In this study we present a detailed structure-function analysis of the interaction of BMP-2 – a prototypic ligand of the TGF-β superfamily – with its type II receptor ActR-IIB. In previous work the determinants for specificity and affinity in type I BMPR-IA and BMPR-IB receptor interaction have been analyzed [32, 33]. Now new crystal structures of ternary complexes comprising BMPR-IA and ActR-IIB ectodomains and either wildtype BMP-2 or a BMP-2 variant with enhanced affinity for ActR-IIB have been elucidated at high resolution. On the basis of the structural information a mutational analysis of ActR-IIB and the interacting BMP-2 knuckle epitope has been performed in order to investigate possible interactions between epitopes as well as determinants for specificity and affinity in type II receptor interaction, in particular with the dual-specificity receptor ActR-IIB. The results reveal a molecular basis for understanding differences in BMP-2, BMP-7 and Act-A signaling. In addition the molecular mechanisms for high- and low-affinity binding to the ActR-IIB receptor have been clarified. The present results will possibly help to design ligand and receptor mutant proteins that can be used to target diseases caused by dysregulation of BMP or activin signaling.
Expression and purification of recombinant proteins
E. coli derived BMP-2 proteins and the receptor ectodomain proteins of BMPR-IA, ActR-II and BMPR-II were expressed and purified as described earlier . The ActR-IIBECD was expressed as thioredoxin-fusion similar to BMPR-IAECD in OrigamiB (DE3) (Novagen) cells. Cells were harvested and lysed by sonication. The fusion protein was isolated from the supernatant by Ni2+-IMAC chromatography, cleaved with 0.5 U thrombin per mg fusion protein (Sigma) and the products subsequently purified by anion exchange chromatography (TMAE, Merck). ActR-IIBECD was finally purified by reversed phase HPLC using a C4 column (Vydac). BMP-2 or ActR-IIBECD variants were constructed by site directed mutagenesis using the QuikChange methodology (Stratagene).
For acquisition of a MAD dataset using Se-Met derivatives, a triple mutant variant of BMPR-IAECD (F35M, L73M, L95M) was generated. Binding properties to BMP-2 were unaltered as tested by interaction analysis. The variant and wildtype BMP-2 were expressed in M9 minimal medium supplemented with 50 mg L-1 DL-Se-Met (Sigma) using the Met-auxotroph E. coli strain B834(DE3) (Novagen).
Crystallization of the ternary ligand-receptor complex
The ternary complexes consisting of BMP-2 or BMP-2 L100K/N102D bound to BMPR-IAECD and ActR-IIBECD were prepared by a stepwise procedure. First the binary BMP-2:BMPR-IAECD complexes were formed and purified as described . The purified binary complexes were then mixed with a 2.2-fold molar excess of ActR-IIBECD in HBS700 buffer (10 mM HEPES, 700 mM NaCl pH7.4) and purified by gel filtration. Stoichiometry and homogeneity of both complexes were analyzed by comparison to mixtures of the components with defined molar ratios using SDS-PAGE and RP-HPLC. For crystallization the protein complexes were concentrated to 15 mg ml-1. Crystals of wildtype BMP-2: BMPR-IAECD:ActR-IIBECD were obtained by hanging-drop vapor diffusion from 50% (v/v) PPG400, 0.1 M Bis-Tris, pH5.8 at 21°C; for the complex comprising the BMP-2 double variant crystallization was achieved from 30% (w/v) PEG3350, 0.1 M Tris-HCl pH8.8, 0.2 M ammonium acetate at 21°C. Crystals of a final size of approximately 250 × 100 × 100 μm grew within 8 days for both complexes.
Data acquisition and structure analysis
Processing and refinement statistics
ternary complex 1:1:1
ternary complex 1:2:2
a = 64.1 Å, b = 65.4 Å, c = 114.1 Å
α = β = γ = 90°
a = b = 82.8 Å, c = 111.1 Å
α = β = 90°, γ = 120°
20.0–1.81 Å (1.89–1.81 Å)
41.4–1.78 Å (1.84–1.78 Å)
Number of measured reflectionsc
Number of unique reflectionsc
Rsym for all reflections
20–1.85 Å (1.92–1.85 Å)
40–1.92 Å (1.99–1.92 Å)
Rfree (Test set 5%)
Cross-validated sigma coordinate error
Residues in most favored region
Residues in additional allowed region
Residues in generously allowed region
Residues in disallowed region
Interaction analysis by surface plasmon resonance
The BIACORE2000 system was used for all biosensor experiments. For measurement of ligand-specific binding capabilities to different type II receptors a streptavidin-modified biosensor CM5 was coated with biotinylated BMP-2 (E. coli), BMP-2 (CHO cells, R&D Systems), BMP-7 (CHO cells, R&D Systems), or Act-A (Sf9 cells)  to a level of about 200 resonance units (1 RU = 1 pg mm-2). Interaction with the type II receptors ActR-IIB, ActR-II  and BMPR-II  was analyzed by recording sensorgrams of the ligand-receptor interactions in HBS500 buffer (10 mM HEPES, pH7.4, 500 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20) using the receptor ectodomain proteins as analyte. Surfaces were regenerated by perfusion for 2 min with 4 M MgCl2. All measurements were corrected for non-specific interactions by subtracting a control sensorgram recorded for flow cell 1. Apparent binding constants (KD) were obtained from the dose dependence of equilibrium binding using 1, 2, 3, 5, 10, 20, and 50 μM concentration of the receptor ectodomain proteins. The mean standard deviations for all KD values were < 20%.
Induction of alkaline phosphatase (ALP) expression
The mouse myoblast cell line C2C12 (ATCC, No. CRL-1772) was cultured in DMEM:HamsF12 (1:1) medium containing 5% fetal calf serum (FCS), and antibiotics (100 U ml-1 penicillin G and 100 μg ml-1 streptomycin). For alkaline phosphatase induction (ALP) assays the cells were serum starved (2% FCS) and exposed to ligands for 72 h in 96-well microplates . After cell lysis ALP activity was measured by p-nitrophenylphosphate conversion using an ELISA reader at 405 nm.
The authors thank M. Gottermeier and C. Söder for excellent technical assistance; we thank W. Schmitz for mass spectrometry analysis. We gratefully acknowledge access to the beamline BL14.1 at BESSY (Protein Structure Factory, Berlin, Germany) and thank M. Fieber-Erdmann for support during data acquisition. The authors thank L. van Geersdaele for critical reading of the manuscript. Access to the local protein structure facility (Virchow Research Center, Würzburg, Germany) is gratefully acknowledged. This project was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 487 TP B1 and B2, and by Fonds der Deutschen Chemischen Industrie.
Coordinates and structure factors have been deposited in the databank RCSB (accession codes 2H62 and 2H62sf for wildtype BMP-2:BMPR-IAECD:ActR-IIBECD and 2H64 and 2H64sf for BMP-2 L100K/N102D:(BMPR-IAECD)2:(ActR-IIBECD)2).
- Hogan BL: Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996, 6(4):432–438. 10.1016/S0959-437X(96)80064-5View ArticlePubMedGoogle Scholar
- Massague J: TGF-ß signal transduction. Annu Rev Biochem 1998, 67: 753–791. 10.1146/annurev.biochem.67.1.753View ArticlePubMedGoogle Scholar
- Reddi AH: Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998, 16(3):247–252. 10.1038/nbt0398-247View ArticlePubMedGoogle Scholar
- Reddi AH, (ed): Bone morphogenetic proteins. Cytokine Growth Factor Rev 2005, 16(3):249–376. 10.1016/j.cytogfr.2005.04.003
- Savage-Dunn C: Targets of TGF ß-related signaling in Caenorhabditis elegans. Cytokine Growth Factor Rev 2001, 12(4):305–312. 10.1016/S1359-6101(01)00015-6View ArticlePubMedGoogle Scholar
- Parker L, Stathakis DG, Arora K: Regulation of BMP and activin signaling in Drosophila. Prog Mol Subcell Biol 2004, 34: 73–101.View ArticlePubMedGoogle Scholar
- Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K: Two major Smad pathways in TGF-ß superfamily signalling. Genes Cells 2002, 7(12):1191–1204. 10.1046/j.1365-2443.2002.00599.xView ArticlePubMedGoogle Scholar
- Mikic B: Multiple effects of GDF-5 deficiency on skeletal tissues: implications for therapeutic bioengineering. Ann Biomed Eng 2004, 32(3):466–476. 10.1023/B:ABME.0000017549.57126.51View ArticlePubMedGoogle Scholar
- Wu XB, Li Y, Schneider A, Yu W, Rajendren G, Iqbal J, Yamamoto M, Alam M, Brunet LJ, Blair HC, Zaidi M, Abe E: Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 2003, 112(6):924–934. 10.1172/JCI200315543PubMed CentralView ArticlePubMedGoogle Scholar
- Tobin JF, Celeste AJ: Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. Drug Discov Today 2006, 11(9–10):405–411. 10.1016/j.drudis.2006.03.016View ArticlePubMedGoogle Scholar
- Lee SJ, McPherron AC: Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev 1999, 9(5):604–607. 10.1016/S0959-437X(99)00004-0View ArticlePubMedGoogle Scholar
- Massague J, Blain SW, Lo RS: TGFß signaling in growth control, cancer, and heritable disorders. Cell 2000, 103(2):295–309. 10.1016/S0092-8674(00)00121-5View ArticlePubMedGoogle Scholar
- ten Dijke P, Miyazono K, Heldin CH: Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol 1996, 8(2):139–145. 10.1016/S0955-0674(96)80058-5View ArticlePubMedGoogle Scholar
- Carcamo J, Weis FM, Ventura F, Wieser R, Wrana JL, Attisano L, Massague J: Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor ß and activin. Mol Cell Biol 1994, 14(6):3810–3821.PubMed CentralPubMedGoogle Scholar
- Shi Y, Massague J: Mechanisms of TGF-ß signaling from cell membrane to the nucleus. Cell 2003, 113(6):685–700. 10.1016/S0092-8674(03)00432-XView ArticlePubMedGoogle Scholar
- Heldin CH, Miyazono K, ten Dijke P: TGF-ß signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390(6659):465–471. 10.1038/37284View ArticlePubMedGoogle Scholar
- Massague J, Seoane J, Wotton D: Smad transcription factors. Genes Dev 2005, 19(23):2783–2810. 10.1101/gad.1350705View ArticlePubMedGoogle Scholar
- Moustakas A, Heldin CH: Non-Smad TGF-ß signals. J Cell Sci 2005, 118(Pt 16):3573–3584. 10.1242/jcs.02554View ArticlePubMedGoogle Scholar
- Hassel S, Eichner A, Yakymovych M, Hellman U, Knaus P, Souchelnytskyi S: Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004, 4(5):1346–1358. 10.1002/pmic.200300770View ArticlePubMedGoogle Scholar
- Canalis E, Economides AN, Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003, 24(2):218–235. 10.1210/er.2002-0023View ArticlePubMedGoogle Scholar
- Larrain J, Oelgeschlager M, Ketpura NI, Reversade B, Zakin L, De Robertis EM: Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling. Development 2001, 128(22):4439–4447.PubMed CentralPubMedGoogle Scholar
- Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, Niehrs C: Silencing of TGF-ß signalling by the pseudoreceptor BAMBI. Nature 1999, 401(6752):480–485. 10.1038/46794View ArticlePubMedGoogle Scholar
- Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38(5):531–539. 10.1038/ng1777View ArticlePubMedGoogle Scholar
- Chen HB, Shen J, Ip YT, Xu L: Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev 2006, 20(6):648–653. 10.1101/gad.1384706PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH: A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999, 400(6745):687–693. 10.1038/23293View ArticlePubMedGoogle Scholar
- Hage T, Sebald W, Reinemer P: Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell 1999, 97(2):271–281. 10.1016/S0092-8674(00)80736-9View ArticlePubMedGoogle Scholar
- Wotton D, Massague J: Smad transcriptional corepressors in TGF ß family signaling. Curr Top Microbiol Immunol 2001, 254: 145–164.PubMedGoogle Scholar
- Kirsch T, Nickel J, Sebald W: BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 2000, 19(13):3314–3324. 10.1093/emboj/19.13.3314PubMed CentralView ArticlePubMedGoogle Scholar
- Nishitoh H, Ichijo H, Kimura M, Matsumoto T, Makishima F, Yamaguchi A, Yamashita H, Enomoto S, Miyazono K: Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 1996, 271(35):21345–21352. 10.1074/jbc.271.35.21345View ArticlePubMedGoogle Scholar
- Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL: Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 1998, 273(40):25628–25636. 10.1074/jbc.273.40.25628View ArticlePubMedGoogle Scholar
- de Caestecker M: The transforming growth factor-ß superfamily of receptors. Cytokine Growth Factor Rev 2004, 15(1):1–11. 10.1016/j.cytogfr.2003.10.004View ArticlePubMedGoogle Scholar
- Nickel J, Kotzsch A, Sebald W, Mueller TD: A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol 2005, 349(5):933–947. 10.1016/j.jmb.2005.04.015View ArticlePubMedGoogle Scholar
- Seemann P, Schwappacher R, Kjaer KW, Krakow D, Lehmann K, Dawson K, Stricker S, Pohl J, Ploger F, Staub E, Nickel J, Sebald W, Knaus P, Mundlos S: Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest 2005, 115(9):2373–2381. 10.1172/JCI25118PubMed CentralView ArticlePubMedGoogle Scholar
- Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-ß superfamily signaling. Faseb J 1999, 13(15):2105–2124.PubMedGoogle Scholar
- Nagaso H, Suzuki A, Tada M, Ueno N: Dual specificity of activin type II receptor ActRIIb in dorso-ventral patterning during zebrafish embryogenesis. Dev Growth Differ 1999, 41(2):119–133. 10.1046/j.1440-169x.1999.00418.xView ArticlePubMedGoogle Scholar
- Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin CH, Miyazono K: Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 1995, 92(17):7632–7636. 10.1073/pnas.92.17.7632PubMed CentralView ArticlePubMedGoogle Scholar
- Gamer LW, Nove J, Levin M, Rosen V: BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in Xenopus embryos. Dev Biol 2005, 285(1):156–168. 10.1016/j.ydbio.2005.06.012View ArticlePubMedGoogle Scholar
- Piek E, Afrakhte M, Sampath K, van Zoelen EJ, Heldin CH, ten Dijke P: Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J Cell Physiol 1999, 180(2):141–149. 10.1002/(SICI)1097-4652(199908)180:2<141::AID-JCP1>3.0.CO;2-IView ArticlePubMedGoogle Scholar
- Kirsch T, Sebald W, Dreyer MK: Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 2000, 7(6):492–496. 10.1038/75903View ArticlePubMedGoogle Scholar
- Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S: The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 2003, 11(3):605–617. 10.1016/S1097-2765(03)00094-7View ArticlePubMedGoogle Scholar
- Thompson TB, Woodruff TK, Jardetzky TS: Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-ß ligand:receptor interactions. EMBO J 2003, 22(7):1555–1566. 10.1093/emboj/cdg156PubMed CentralView ArticlePubMedGoogle Scholar
- Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S: A flexible activin explains the membrane-dependent cooperative assembly of TGF-ß family receptors. Mol Cell 2004, 15(3):485–489. 10.1016/j.molcel.2004.07.011View ArticlePubMedGoogle Scholar
- Allendorph GP, Vale WW, Choe S: Structure of the ternary signaling complex of a TGF-ß superfamily member. Proc Natl Acad Sci U S A 2006, 103(20):7643–7648. 10.1073/pnas.0602558103PubMed CentralView ArticlePubMedGoogle Scholar
- Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP: Crystal structure of the human TßR2 ectodomain--TGF-ß3 complex. Nat Struct Biol 2002, 9(3):203–208.PubMedGoogle Scholar
- Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvonen M: Structural basis for the inhibition of activin signalling by follistatin. Embo J 2006, 25(5):1035–1045. 10.1038/sj.emboj.7601000PubMed CentralView ArticlePubMedGoogle Scholar
- Bocharov EV, Korzhnev DM, Blommers MJ, Arvinte T, Orekhov VY, Billeter M, Arseniev AS: Dynamics-modulated biological activity of transforming growth factor ß3. J Biol Chem 2002, 277(48):46273–46279. 10.1074/jbc.M206274200View ArticlePubMedGoogle Scholar
- Zuniga JE, Groppe JC, Cui Y, Hinck CS, Contreras-Shannon V, Pakhomova ON, Yang J, Tang Y, Mendoza V, Lopez-Casillas F, Sun L, Hinck AP: Assembly of TßRI:TßRII:TGFß ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent. J Mol Biol 2005, 354(5):1052–1068. 10.1016/j.jmb.2005.10.014View ArticlePubMedGoogle Scholar
- Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD: Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 2004, 11(5):481–488. 10.1038/nsmb756View ArticlePubMedGoogle Scholar
- Dill KA: Dominant forces in protein folding. Biochemistry 1990, 29(31):7133–7155. 10.1021/bi00483a001View ArticlePubMedGoogle Scholar
- Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W: Identification of a binding site on the type II activin receptor for activin and inhibin. J Biol Chem 2000, 275(5):3206–3212. 10.1074/jbc.275.5.3206View ArticlePubMedGoogle Scholar
- Knaus P, Sebald W: Cooperativity of binding epitopes and receptor chains in the BMP/TGFß superfamily. Biol Chem 2001, 382(8):1189–1195. 10.1515/BC.2001.149View ArticlePubMedGoogle Scholar
- Wuytens G, Verschueren K, de Winter JP, Gajendran N, Beek L, Devos K, Bosman F, de Waele P, Andries M, van den Eijnden-van Raaij AJ, Smith JC, Huylebroeck D: Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. J Biol Chem 1999, 274(14):9821–9827. 10.1074/jbc.274.14.9821View ArticlePubMedGoogle Scholar
- Chalaux E, Lopez-Rovira T, Rosa JL, Bartrons R, Ventura F: JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. J Biol Chem 1998, 273(1):537–543. 10.1074/jbc.273.1.537View ArticlePubMedGoogle Scholar
- Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH, Rosenbaum JS: Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J Biol Chem 1995, 270(38):22522–22526. 10.1074/jbc.270.38.22522View ArticlePubMedGoogle Scholar
- Liu F, Ventura F, Doody J, Massague J: Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995, 15(7):3479–3486.PubMed CentralPubMedGoogle Scholar
- Attisano L, Wrana JL, Montalvo E, Massague J: Activation of signalling by the activin receptor complex. Mol Cell Biol 1996, 16(3):1066–1073.PubMed CentralPubMedGoogle Scholar
- Frisch A, Wright CV: XBMPRII, a novel Xenopus type II receptor mediating BMP signaling in embryonic tissues. Development 1998, 125(3):431–442.PubMedGoogle Scholar
- Kirsch T, Nickel J, Sebald W: Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2. FEBS Lett 2000, 468(2–3):215–219. 10.1016/S0014-5793(00)01214-XView ArticlePubMedGoogle Scholar
- Cronin CN, Thompson DA, Martin F: Expression of bovine activin-A and inhibin-A in recombinant baculovirus-infected Spodoptera frugiperda Sf 21 insect cells. Int J Biochem Cell Biol 1998, 30(10):1129–1145. 10.1016/S1357-2725(98)00077-6View ArticlePubMedGoogle Scholar
- Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa Sehara A, Suda T: Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J Cell Biol 1995 Feb;128(4):following 713]. J Cell Biol 1994, 127(6 Pt 1):1755–1766. 10.1083/jcb.127.6.1755View ArticlePubMedGoogle Scholar
- De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y, Baardsnes J, Mendoza V, Sun L, Lopez-Casillas F, O'Connor-McCourt M, Hinck AP: Three key residues underlie the differential affinity of the TGFß isoforms for the TGFß type II receptor. J Mol Biol 2006, 355(1):47–62. 10.1016/j.jmb.2005.10.022View ArticlePubMedGoogle Scholar
- Sebald W, Nickel J, Zhang JL, Mueller TD: Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 2004, 385(8):697–710. 10.1515/BC.2004.086View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.